Literature DB >> 20846829

Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008.

Francis F Arhin, Gregory Moeck, Deborah C Draghi, Chris M Pillar, Daniel F Sahm.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20846829     DOI： 10.1016/j.ijantimicag.2010.07.010

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  3 in total

Review 1.  Oritavancin: a review in acute bacterial skin and skin structure infections.

Authors:  Yahiya Y Syed; Lesley J Scott
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

2.  Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010.

Authors:  Rodrigo E Mendes; Leah N Woosley; David J Farrell; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

3.  Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.

Authors:  Lala M Dunbar; Joe Milata; Ty McClure; Margaret M Wasilewski
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.